72 related articles for article (PubMed ID: 19743500)
1. Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy.
Chiang PC; Kishore NN; Thompson DC
J Pharm Sci; 2010 Mar; 99(3):1278-87. PubMed ID: 19743500
[TBL] [Abstract][Full Text] [Related]
2. A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.
Mbalaviele G; Sommers CD; Bonar SL; Mathialagan S; Schindler JF; Guzova JA; Shaffer AF; Melton MA; Christine LJ; Tripp CS; Chiang PC; Thompson DC; Hu Y; Kishore N
J Pharmacol Exp Ther; 2009 Apr; 329(1):14-25. PubMed ID: 19168710
[TBL] [Abstract][Full Text] [Related]
3. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
Sommers CD; Thompson JM; Guzova JA; Bonar SL; Rader RK; Mathialagan S; Venkatraman N; Holway VW; Kahn LE; Hu G; Garner DS; Huang HC; Chiang PC; Schindler JF; Hu Y; Meyer DM; Kishore NN
J Pharmacol Exp Ther; 2009 Aug; 330(2):377-88. PubMed ID: 19478133
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.
Rajendrasozhan S; Hwang JW; Yao H; Kishore N; Rahman I
Pulm Pharmacol Ther; 2010 Jun; 23(3):172-81. PubMed ID: 20080200
[TBL] [Abstract][Full Text] [Related]
5. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Izmailova ES; Paz N; Alencar H; Chun M; Schopf L; Hepperle M; Lane JH; Harriman G; Xu Y; Ocain T; Weissleder R; Mahmood U; Healy AM; Jaffee B
Arthritis Rheum; 2007 Jan; 56(1):117-28. PubMed ID: 17195214
[TBL] [Abstract][Full Text] [Related]
6. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.
Catley MC; Sukkar MB; Chung KF; Jaffee B; Liao SM; Coyle AJ; Haddad el-B; Barnes PJ; Newton R
Mol Pharmacol; 2006 Aug; 70(2):697-705. PubMed ID: 16687566
[TBL] [Abstract][Full Text] [Related]
7. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Schopf L; Savinainen A; Anderson K; Kujawa J; DuPont M; Silva M; Siebert E; Chandra S; Morgan J; Gangurde P; Wen D; Lane J; Xu Y; Hepperle M; Harriman G; Ocain T; Jaffee B
Arthritis Rheum; 2006 Oct; 54(10):3163-73. PubMed ID: 17009244
[TBL] [Abstract][Full Text] [Related]
8. Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma.
Birrell MA; Hardaker E; Wong S; McCluskie K; Catley M; De Alba J; Newton R; Haj-Yahia S; Pun KT; Watts CJ; Shaw RJ; Savage TJ; Belvisi MG
Am J Respir Crit Care Med; 2005 Oct; 172(8):962-71. PubMed ID: 16002568
[TBL] [Abstract][Full Text] [Related]
9. The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator.
Brandish PE; Anderson K; Baltus GA; Bai C; Bungard CJ; Bunting P; Byford A; Chiu CS; Cicmil M; Corcoran H; Euler D; Fisher JE; Gambone C; Hasbun-Manning M; Kuklin N; Landis E; Lifsted TQ; McElwee-Witmer S; McIntosh IS; Meissner RS; Miao J; Mitchell HJ; Musselman A; Schmidt A; Shin J; Szczerba P; Thompson CD; Tribouley C; Vogel RL; Warrier S; Hershey JC
Eur J Pharmacol; 2014 Feb; 724():102-11. PubMed ID: 24374007
[TBL] [Abstract][Full Text] [Related]
10. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats.
Wang Y; Fang Y; Huang W; Zhou X; Wang M; Zhong B; Peng D
J Ethnopharmacol; 2005 Apr; 98(1-2):37-43. PubMed ID: 15763362
[TBL] [Abstract][Full Text] [Related]
11. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.
Shimizu H; Yamasaki T; Yoneda Y; Muro F; Hamada T; Yasukochi T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Aug; 21(15):4550-5. PubMed ID: 21705219
[TBL] [Abstract][Full Text] [Related]
12. IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic.
Birrell MA; Wong S; Hardaker EL; Catley MC; McCluskie K; Collins M; Haj-Yahia S; Belvisi MG
Mol Pharmacol; 2006 Jun; 69(6):1791-800. PubMed ID: 16517756
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
Ushiyama S; Yamada T; Murakami Y; Kumakura S; Inoue S; Suzuki K; Nakao A; Kawara A; Kimura T
Eur J Pharmacol; 2008 Jan; 578(1):76-86. PubMed ID: 17920584
[TBL] [Abstract][Full Text] [Related]
14. Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.
Gillooly KM; Pattoli MA; Taylor TL; Chen L; Cheng L; Gregor KR; Whitney GS; Susulic V; Watterson SH; Kempson J; Pitts WJ; Booth-Lute H; Yang G; Davies P; Kukral DW; Strnad J; McIntyre KW; Darienzo CJ; Salter-Cid L; Yang Z; Wang-Iverson DB; Burke JR
J Pharmacol Exp Ther; 2009 Nov; 331(2):349-60. PubMed ID: 19652024
[TBL] [Abstract][Full Text] [Related]
15. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
[TBL] [Abstract][Full Text] [Related]
16. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.
Tsai J; Zhang R; Qiu W; Su Q; Naples M; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1287-98. PubMed ID: 19342510
[TBL] [Abstract][Full Text] [Related]
18. Development and assessment of a complete-detoxication strategy for Fuzi (lateral root of Aconitum carmichaeli) and its application in rheumatoid arthritis therapy.
Tong P; Wu C; Wang X; Hu H; Jin H; Li C; Zhu Y; Shan L; Xiao L
J Ethnopharmacol; 2013 Mar; 146(2):562-71. PubMed ID: 23376046
[TBL] [Abstract][Full Text] [Related]
19. Integration of efficacy, pharmacokinetic and safety assessment of interleukin-1 receptor antagonist in a preclinical model of arthritis.
Zuurmond AM; Koudijs A; van El B; Doornbos RP; van Manen-Vernooij BC; Bastiaans JH; Penninks AH; van Bilsen JH; Cnubben NH; Degroot J
Regul Toxicol Pharmacol; 2011 Apr; 59(3):461-70. PubMed ID: 21300126
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
